File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0024454335
- PMID: 2511831
- WOS: WOS:A1989AZ03400006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Treatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelin
Title | Treatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelin |
---|---|
Authors | |
Keywords | luteinizing hormone‐releasing hormone analogue precocious puberty |
Issue Date | 1989 |
Citation | Australian Paediatric Journal, 1989, v. 25 n. 5, p. 274-278 How to Cite? |
Abstract | Fourteen aptients with precocious puberty were treated for 1-3 years with 900-1800 μg/day of intranasal (i.n.) Buserelin. The peak luteinizing hormone and follicle-stimulating hormone responses to intravenous luteinizing hormone-releasing hormone were reduced significantly 4 weeks after starting treatment and remained suppressed while the patients were on treatment. Two patients were withdrawn because of drug non-compliance. Three patients showed regression of pubertal changes, four patients showed no progression and five patients showed progression of breast size or pubic hair staging after 1.5-2 years of treatment. Treatment was changed to the subcutaneous route in two patients because of hormonal escape and accelerated skeletal maturation. The mean growth velocity decreased from 10.78 cm/year (s.e.m. = 0.64) to 7.06 cm/year (s.e.m. = 0.85) after 1 year of treatment (P < 0.005). After an increase in dosage (from 900 μg/day to 1800 μg/day) in most patients, further significant falls in growth velocity to 5.29 cm/year (s.e.m. = 0.45), 4.63 cm/year (s.e.m. = 0.8) and 5.06 cm/year (s.e.m. = 0.5) were observed at 18, 24 and 30 months, respectively, compared with the pretreatment value (P < 0.001). With treatment, the increased rate of skeletal maturation normalized. In 10 patients who had completed 2 years of treatment, the height standard deviation score for bone age improved from a pretreatment value of -2.42 ± 0.42 to -1.6 ± 0.42 after 2 years of treatment (P < 0.01), indicating an improvement in height prognosis. It is concluded that i.n. Buserelin at a dose of 1800 μg/day is effective in the treatment of most but not all patients with precocious puberty. |
Persistent Identifier | http://hdl.handle.net/10722/170237 |
ISSN | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Low, LCK | en_HK |
dc.contributor.author | Wang, C | en_HK |
dc.contributor.author | Cheung, PT | en_HK |
dc.contributor.author | Chan, FL | en_HK |
dc.date.accessioned | 2012-10-30T06:06:53Z | - |
dc.date.available | 2012-10-30T06:06:53Z | - |
dc.date.issued | 1989 | en_HK |
dc.identifier.citation | Australian Paediatric Journal, 1989, v. 25 n. 5, p. 274-278 | en_HK |
dc.identifier.issn | 0004-993X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/170237 | - |
dc.description.abstract | Fourteen aptients with precocious puberty were treated for 1-3 years with 900-1800 μg/day of intranasal (i.n.) Buserelin. The peak luteinizing hormone and follicle-stimulating hormone responses to intravenous luteinizing hormone-releasing hormone were reduced significantly 4 weeks after starting treatment and remained suppressed while the patients were on treatment. Two patients were withdrawn because of drug non-compliance. Three patients showed regression of pubertal changes, four patients showed no progression and five patients showed progression of breast size or pubic hair staging after 1.5-2 years of treatment. Treatment was changed to the subcutaneous route in two patients because of hormonal escape and accelerated skeletal maturation. The mean growth velocity decreased from 10.78 cm/year (s.e.m. = 0.64) to 7.06 cm/year (s.e.m. = 0.85) after 1 year of treatment (P < 0.005). After an increase in dosage (from 900 μg/day to 1800 μg/day) in most patients, further significant falls in growth velocity to 5.29 cm/year (s.e.m. = 0.45), 4.63 cm/year (s.e.m. = 0.8) and 5.06 cm/year (s.e.m. = 0.5) were observed at 18, 24 and 30 months, respectively, compared with the pretreatment value (P < 0.001). With treatment, the increased rate of skeletal maturation normalized. In 10 patients who had completed 2 years of treatment, the height standard deviation score for bone age improved from a pretreatment value of -2.42 ± 0.42 to -1.6 ± 0.42 after 2 years of treatment (P < 0.01), indicating an improvement in height prognosis. It is concluded that i.n. Buserelin at a dose of 1800 μg/day is effective in the treatment of most but not all patients with precocious puberty. | en_HK |
dc.language | eng | en_US |
dc.relation.ispartof | Australian Paediatric Journal | en_HK |
dc.subject | luteinizing hormone‐releasing hormone analogue | - |
dc.subject | precocious puberty | - |
dc.subject.mesh | Administration, Intranasal | en_US |
dc.subject.mesh | Buserelin - Administration & Dosage | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Child, Preschool | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gonadal Steroid Hormones - Blood | en_US |
dc.subject.mesh | Hong Kong | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Long-Term Care | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Puberty, Precocious - Blood - Drug Therapy | en_US |
dc.subject.mesh | Sexual Maturation - Drug Effects | en_US |
dc.title | Treatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelin | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Low, LCK: lcklow@hkucc.hku.hk | en_HK |
dc.identifier.email | Cheung, PT: ptcheung@hku.hk | en_HK |
dc.identifier.authority | Low, LCK=rp00337 | en_HK |
dc.identifier.authority | Cheung, PT=rp00351 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 2511831 | - |
dc.identifier.scopus | eid_2-s2.0-0024454335 | en_HK |
dc.identifier.volume | 25 | en_HK |
dc.identifier.issue | 5 | en_HK |
dc.identifier.spage | 274 | en_HK |
dc.identifier.epage | 278 | en_HK |
dc.identifier.isi | WOS:A1989AZ03400006 | - |
dc.identifier.scopusauthorid | Low, LCK=7007049461 | en_HK |
dc.identifier.scopusauthorid | Wang, C=7501631357 | en_HK |
dc.identifier.scopusauthorid | Cheung, PT=7202595465 | en_HK |
dc.identifier.scopusauthorid | Chan, FL=7202586444 | en_HK |
dc.identifier.issnl | 0004-993X | - |